Dabigatran for Mitral Stenosis Atrial Fibrillation
Status:
Recruiting
Trial end date:
2024-09-30
Target enrollment:
Participant gender:
Summary
Atrial fibrillation (AF) is the most common sustained cardiac arrythmia encountered in
clinical practice and patients suffer from this are at increased risk of ischemic stroke and
systemic thromboembolism due to the formation and embolism of left atrial thrombi. Current
international guidelines recommend non-vitamin K oral anticoagulants (NOACs) for stroke
prevention amongst these patients with non-valvular AF at significant ischemic stroke risk,
given the superior safety and comparable efficacy of NOACs over warfarin. However, warfarin
therapy remains in the stroke prevention strategy for AF patients with mitral stenosis (MS)
as NOACs lack of evidence for safety and efficacy amongst this group of patients. A local
study is initiated to compare and evaluate the safety and efficacy among the two groups of
anticoagulants - NOACs and traditional Warfarin therapy - in AF patients with underlying
moderate to severe MS.